TG Therapeutics, Inc. announced on Monday that its multiple sclerosis (MS) medication, Briumvi, has been launched in Germany by its ex-US commercial partner, Neuraxpharm Group. This marks the drug's debut in Europe.
Under the terms of their partnership, TG Therapeutics is due to receive a $12.5 million payment from Neuraxpharm for the inaugural European launch of Briumvi.
Currently, Briumvi is available for MS patients in the United States. It is indicated for the treatment of various forms of the disease including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS, in adults. The medication has also earned approval from the European Commission and the UK's Medicines and Healthcare Products Regulatory Agency for use in treating patients with relapsing forms of MS.
